Takeda, the originator of Actos, said that it helps reduce insulin resistance. In Japan, Actos tablets were approved and launched in 1999, and a New Drug Application for the new OD tablet formulation was submitted in September 2008.
The company claims that Actos OD tablets swiftly disintegrate in the oral cavity and can be taken easily without water. This is expected to improve patient dosing compliance and promote better glycemic control. The approved indications, dosage and administration of Actos OD tablets are the same as those for currently marketed Actos tablets.
Takeda has already developed and is marketing OD tablets formulation of Voglibose (Basen) for the improvement of postprandial hyperglycemia. The company believes Actos OD tablets will contribute to the treatment of type 2 diabetes and will strive to further maintain and enhance its diabetes franchise.